Masahiko Zuka

Prof. Dr. Masahiko Zuka


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2011 in Legal Medicine
Verified
Journal Article
Closed access
PDF file
MZMasahiko Zuka
Masahiko Zuka
TOTamehito Onoe
Tamehito Onoe
MKMitsuhiro Kawano
Mitsuhiro Kawano
MYMasakazu Yamagishi
Masakazu Yamagishi
TOTohru Ohshima
Tohru Ohshima

1 August 2012 in Journal of Forensic and Legal Medicine
Verified
Journal Article
Closed access
MZMasahiko Zuka
Masahiko Zuka
SCSatoshi Chinaka
Satoshi Chinaka
YMYutaka Matsumoto
Yutaka Matsumoto
NTNariaki Takayama
Nariaki Takayama
YHYoshiaki Hitomi
Yoshiaki Hitomi
TOTohru Ohshima
Tohru Ohshima

4 September 2025 in Toxins
Verified
Journal Article
Open access
PDF file
CMChiyono Morimoto
Chiyono Morimoto
SASho Amatsu
Sho Amatsu
TMTakuhiro Matsumura
Takuhiro Matsumura
MZMasahiko Zuka
Masahiko Zuka
YFYukako Fujinaga
Yukako Fujinaga
Botulinum toxin (BoNT) causes flaccid paralysis by blocking the release of neurotransmitters. BoNTs associate with neurotoxin-associated proteins to form medium and large progenitor toxin complexes. The large progenitor toxin complex serotype A-62A (L-PTC/A-62A) specifically targets intestinal M cells for invasion, whereas large progenitor toxin complex serotype B-Okra (L-PTC/B-Okra) is mainly taken up by enterocytes and exhibits higher toxicity via the oral route. Hemagglutinin (HA) is a neurotoxin-associated protein that promotes BoNT absorption from the intestine and has carbohydrate-binding and barrier-disrupting activities. In this study, we established an in vitro reconstitution and purification system for recombinant L-PTC/B-Okra and created a recombinant L-PTC/B-Okra mutant rL-PTC/B-KA with carbohydrate-binding activity but not barrier-disrupting activity. rL-PTC/B-KA showed significantly reduced oral toxicity. Our results demonstrate that the B-Okra toxin disrupts the epithelial barrier of enterocytes and exerts oral toxicity.

1 May 2013 in Forensic Science International
Verified
Journal Article
Closed access
MZMasahiko Zuka
Masahiko Zuka
TOTohru Ohshima
Tohru Ohshima

10 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CMChiyono Morimoto
Chiyono Morimoto
SASho Amatsu
Sho Amatsu
TMTakuhiro Matsumura
Takuhiro Matsumura
MZMasahiko Zuka
Masahiko Zuka
YFYukako Fujinaga
Yukako Fujinaga
Botulinum toxin (BoNT) causes flaccid paralysis by blocking the release of neurotransmitters. BoNTs associate with neurotoxin-associated proteins (NAPs) to form a medium progenitor toxin complex (PTC) (M-PTC) and large PTC (L-PTC). The L-PTC serotype A-62A (L-PTC/A_62A) specifically targets intestinal M cells for invasion, whereas L-PTC serotype B-Okra (L-PTC/B_Okra), which exhibits higher oral toxicity, is mainly taken up by enterocytes. Hemagglutinin (HA) is a NAPs that promotes BoNT absorption from the intestine and has carbohydrate-binding and barrier-disrupting activities. In this study, we established an in vitro reconstitution and purification system for recombinant L-PTC/B_Okra and created a recombinant L-PTC/B_Okra mutant rL-PTC/BB-KA with carbohydrate-binding activity but not barrier-disrupting activity. rL-PTC/BB-KA significantly reduced the oral toxicity. Our results demonstrate that the toxin of B-Okra disrupts the epithelial barrier of enterocytes and exerts oral toxicity.

4 April 2025 in Legal Medicine
Verified
Journal Article
Closed access
RNRyota Nakanishi
Ryota Nakanishi
TETakahiro Eida
Takahiro Eida
THTomoyoshi Hariba
Tomoyoshi Hariba
SMSatoru Minabe
Satoru Minabe
AMAsami S. Mashio
Asami S. Mashio
MZMasahiko Zuka
Masahiko Zuka